Moxif 400

Moxifloxacin USP 400 mg

COMPOSITION

Moxif 400 mg Tablet: Each film coated tablet contains Moxifloxacin Hydrochloride USP equivalent to 400 mg Moxifloxacin.

DESCRIPTION

Moxifloxacin is an 8-methoxy-fluoroquinolone antibiotic with a broad spectrum of activity and bactericidal action. Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative organisms, anaerobes and atypicals e.g., Chlamydia spp., Mycoplasma spp. and Legionella spp. The bactericidal action results from the interference with topoisomerase II and IV. Topoisomerases are essential enzymes that control DNA topology and assist in DNA replication, repair and transcription. Moxifloxacin is effective against β-lactam and macrolide resistant bacteria.

INDICATIONS

Moxif tablet are indicated for the treatment of adults (>18 years of age) with following bacterial infections:

1. Acute exacerbations of chronic bronchitis
2. Community acquired pneumonia
3. Acute bacterial sinusitis
4. Skin and soft tissue infections (including diabetic foot infections)
5. Typhoid fever
6. Intra-abdominal infections (including polymicrobial infections such as abscesses)
7. Pelvic inflammatory disease

DOSAGE AND ADMINISTRATION

Adult: The recommended dose of Moxif is 400 mg once daily. The duration of therapy depends on the type of infections as described in the following table:

Infection	Dose	Duration
Acute exacerbations of chronic bronchitis	400 mg once daily	5-10 days
Community acquired pneumonia	400 mg once daily	7-14 days
Acute bacterial sinusitis	400 mg once daily	7-10 days
Skin and skin structure infections	400 mg once daily	7-21 days
Typhoid fever/ enteric fever	400 mg once daily	7-10 days
Intra-abdominal infections	400 mg once daily	5-14 days
Pelvic inflammatory disease	400 mg once daily	14 days

Elderly: No adjustment of dosage is required in the elderly.

Children: Efficacy and safety of Moxifloxacin in children and adolescents have not been established.

Renal or hepatic patient: No dosage adjustment is required in patients with renal or hepatic impairment.

CONTRAINDICATION

Moxifloxacin is contraindicated in persons with a history of hypersensitivity to moxifloxacin or any other quinolone.

PRECAUTION

Moxifloxacin has been shown to prolong the QT interval in some patients. It should be avoided in patients with known prolongation, hypokalemia and with drugs that prolong the QT interval. Moxifloxacin should be discontinued at the ¬first appearance of a skin rash or any other sign of hypersensitivity. Moxifloxacin should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon.

SIDE EFFECT

Most side effects reported with Moxifloxacin treatment are mild to moderate in nature and require no treatment. The following side effects may be observed: QT prolongation, tendinopathy and tendon rupture, hypersensitivity reactions, diarrhea, nausea, headache and dizziness.

Use in pregnancy & lactation

Moxifloxacin is Pregnancy Category C drug. Moxifloxacin is not recommended during pregnancy & lactation.

DRUG INTERACTION

Antacids, sucralfate, multivitamins and other products containing multivalent cations (e.g. magnesium) reduces the absorption of Moxifloxacin. Moxifloxacin should be administered 4 hours before or 8 hours after antacids, sucralfate, multivitamins and other products with multivalent cations. NSAID may increase the risk of CNS stimulation. Warfarin may increase the risk of bleeding.

OVERDOSE

In the events of an acute overdose, the stomach should be emptied. The patient should be kept under observation and appropriate hydration should be maintained.

STORAGE

Store at 15^{O}C to 30^{O}C. Protect from light and moisture, keep in a dry place. Keep out of reach of children.

COMMERCIAL PACK

Moxif 400 mg Tablet: Each box containing 1x10 tablets in Alu-Alu blister pack.

Manufactured by

BIOPHARMA
L I M I T E D
A-116, BSCIC Industrial Estate
TONGI, GAZIPUR, BANGLADESH

For further query on the use of this medicine, consult to a registered Doctor or Pharmacist.